Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $17000.0.

  • Ovid Therapeutics' Depreciation and Depletion fell 8380.95% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $256000.0, marking a year-over-year decrease of 3452.69%. This contributed to the annual value of $400000.0 for FY2024, which is 0.0% changed from last year.
  • Ovid Therapeutics' Depreciation and Depletion amounted to $17000.0 in Q3 2025, which was down 8380.95% from $61000.0 recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Depreciation and Depletion peaked at $131632.0 during Q4 2022, and registered a low of $16497.0 during Q3 2021.
  • Over the past 5 years, Ovid Therapeutics' median Depreciation and Depletion value was $87000.0 (recorded in 2025), while the average stood at $71600.1.
  • As far as peak fluctuations go, Ovid Therapeutics' Depreciation and Depletion soared by 51872.46% in 2022, and later tumbled by 8380.95% in 2025.
  • Ovid Therapeutics' Depreciation and Depletion (Quarter) stood at $23897.0 in 2021, then skyrocketed by 450.83% to $131632.0 in 2022, then plummeted by 37.71% to $82000.0 in 2023, then rose by 10.98% to $91000.0 in 2024, then plummeted by 81.32% to $17000.0 in 2025.
  • Its last three reported values are $17000.0 in Q3 2025, $61000.0 for Q2 2025, and $87000.0 during Q1 2025.